Mendelian randomization evaluation of causal effects of fibrinogen on incident coronary heart disease
Year: 2019
Type: article
Study design: Observational Study
Abstract: Background Fibrinogen is an essential hemostatic factor and cardiovascular disease risk factor. Early attempts at evaluating the causal effect of fibrinogen on coronary heart disease (CHD) and myocardial infraction (MI) using Mendelian randomization (MR) used single variant approaches, and did not take advantage of recent genome-wide association studies (GWAS) or multi-variant, pleiotropy robust MR methodologies. Methods and Findings We evaluated evidence for a causal effect of fibrinogen on both CHD and MI using MR. We used both an allele score approach and pleiotropy robust MR models. The allele score was composed of 38 fibrinogen-associated variants from recent GWAS. Initial analyses using the allele score incorporated data from 11 European-ancestry prospective cohorts to examine incidence CHD and MI. We also applied 2 sample MR methods with data from a prevalent CHD and MI GWAS. Results are given in terms of the hazard ratio (HR) or odds ratio (OR), depending on the study design, and associated 95% confidence interval (CI). In single variant analyses no causal effect of fibrinogen on CHD or MI was observed. In multi-variant analyses using incidence CHD cases and the allele score approach, the estimated causal effect (HR) of a 1 g/L higher fibrinogen concentration was 1.62 (CI = 1.12, 2.36) when using incident cases and the allele score approach. In 2 sample MR analyses that accounted for pleiotropy, the causal estimate (OR) was reduced to 1.18 (CI = 0.98, 1.42) and 1.09 (CI = 0.89, 1.33) in the 2 most precise (smallest CI) models, out of 4 models evaluated. In the 2 sample MR analyses for MI, there was only very weak evidence of a causal effect in only 1 out of 4 models. Conclusions A small causal effect of fibrinogen on CHD is observed using multi-variant MR approaches which account for pleiotropy, but not single variant MR approaches. Taken together, results indicate that even with large sample sizes and multi-variant approaches MR analyses still cannot exclude the null when estimating the causal effect of fibrinogen on CHD, but that any potential causal effect is likely to be much smaller than observed in epidemiological studies. Author Summary Initial Mendelian Randomization (MR) analyses of the causal effect of fibrinogen on coronary heart disease (CHD) utilized single variants and did not take advantage of modern, multivariant approaches. This manuscript provides an important update to these initial analyses by incorporating larger sample sizes and employing multiple, modern multi-variant MR approaches to account for pleiotropy. We used incident cases to perform a MR study of the causal effect of fibrinogen on incident CHD and the nested outcome of myocardial infarction (MI) using an allele score approach. Then using data from a case-control genome-wide association study for CHD and MI we performed two sample MR analyses with multiple, pleiotropy robust approaches. Overall, the results indicated that associations between fibrinogen and CHD in observational studies are likely upwardly biased from any underlying causal effect. Single variant MR approaches show little evidence of a causal effect of fibrinogen on CHD or MI. Multi-variant MR analyses of fibrinogen on CHD indicate there may be a small positive effect, however this result needs to be interpreted carefully as the 95% confidence intervals were still consistent with a null effect. Multi-variant MR approaches did not suggest evidence of even a small causal effect of fibrinogen on MI.
Source: PLoS ONE
Authors: Cavin K. Ward-Caviness, Paul S. de Vries, Kerri L. Wiggins, MS, Jennifer E. Huffman, Jennifer E. Huffman, Lisa R. Yanek, Lawrence F. Bielak, Franco Giulianini, Xiuqing Guo, Marcus E. Kleber, Tim Kacprowski, Stefan Groβ, George Davey Smith, Fernando P. Hartwig, Jack Bowden, Gibran Hemani, Martina Müller-Nuraysid, Konstantin Strauch, Wolfgang Koenig, Melanie Waldenberger, Thomas Meitinger, Nathan Pankratz, Eric Boerwinkle, Weihong Tang, Yi-Ping Fu, Andrew D Johnson, Ci Song, Ci Song, Moniek P.M. de Maat, André G. Uitterlinden, Oscar H. Franco, Jennifer A. Brody, Barbara McKnight, Yii-Der Ida Chen, Bruce M. Psaty, Rasika A. Mathias, Diane M. Becker, Patricia A. Peyser, Jennifer A. Smith, Suzette J. Bielinski, Paul M. Ridker, Kent D. Taylor, Jie Yao, Russell Tracy, Graciela Delgado, Stella Trompet, Naveed Sattar, J. Wouter Jukema, Lewis C. Becker, Sharon L.R. Kardia, Jerome I. Rotter, Winfried März, Marcus Dörr, Daniel I. Chasman, Abbas Dehghan, Christopher J. O’Donnell, Nicholas L. Smith, Annette Peters, Alanna C. Morrison
Institutions: Helmholtz Munich, Erasmus MC, The University of Texas Health Science Center at Houston, University of Washington, National Institutes of Health, National Heart, Lung, and Blood Institute, Framingham Heart Study, Johns Hopkins University, Johns Hopkins Medicine, University of Michigan, Brigham and Women's Hospital, The Lundquist Institute, Harbor–UCLA Medical Center, Heidelberg University, Medizinische Fakultät Mannheim, Friedrich Schiller University Jena, Universität Greifswald, German Centre for Cardiovascular Research, Technical University of Munich, Universitätsmedizin Greifswald, University of Bristol, MRC Integrative Epidemiology Unit, Universidade Federal de Pelotas, Ludwig-Maximilians-Universität München, Institut für Medizinische Informationsverarbeitung, Biometrie und Epidemiologie, Universität Ulm, Deutsches Herzzentrum München, University Hospital Ulm, Institut für Humangenetik, University of Minnesota, Baylor College of Medicine, Group Health Cooperative, Kaiser Permanente Washington Health Research Institute, Mayo Clinic, University of Vermont, University of Vermont Medical Center, Leiden University Medical Center, University of Glasgow, Medical University of Graz, Synlab (Germany), Imperial College London, VA Boston Healthcare System, United States Department of Veterans Affairs, VA Office of Research and Development, Seattle Epidemiologic Information and Research Center
Language: English
Subfield: Genetics
Domain: Life Sciences
Open Access status: gold
Estimated APC paid: $1,595
Funders: U.S. Department of Health and Human Services, Amgen, Pfizer, AstraZeneca, GlaxoSmithKline, Sanofi, McKnight Foundation, Yale University, Alexion Pharmaceuticals, Danone, Wellcome Trust, Medicines Company, Kowa Company, Singulex, National Institutes of Health, Medical Research Council, National Heart, Lung, and Blood Institute
Awards: Population genomic variation, functional biology, and the risk of venous thrombosis, CHS research resources for the cardiovascular health of older adults, G3696935633, Genetic Mechanisms of Arteriosclerosis in Hypertensive Sibships, Pre-DETERMINE: Biologic Markers and MRI SCD Cohort Study, The causal map of the human phenome, CHARGE consortium: omics discovery for CVD and aging phenotypes, G7990456425, Using genomics and functional biology to understand fibrinogen and factor XIII and their effects on thrombotic diseases, Analysis of Whole Genome Sequence and Hemostasis Phenotypes
OpenAlex ID: W2944244670
